Results 111 to 120 of about 54,330 (287)

Development and Structural Characterization of UTE‐156, a Covalent Inhibitor of the VCP/p97 AAA+ ATPase

Advanced Science, Volume 13, Issue 25, 4 May 2026.
The AAA+ ATPase Valosin‐containing protein (VCP/p97) regulates protein homeostasis by unfolding ubiquitinated substrates. Here, we describe UTE‐156, a novel irreversible covalent inhibitor that modifies Cys522 in the D2 ATPase motor domain. Although its pharmacochemical limitations preclude immediate therapeutic use, UTE‐156 serves as a valuable ...
Daniela Tamayo‐Jaramillo, Subramanya Hegde, Xuan Jia, Kimberly Coffman, Hariprasad Vankayalapati, David Bearss, Kevin B. Jones, Alex W. Stark, Peter S. Shen   +8 more
wiley   +1 more source

Eccrine poromatosis following chemotherapy and radiation therapy [PDF]

, 2019
Eccrine poroma presents as a single, symptomless erythematous papule in areas with a high density of eccrine sweat glands. Although rare, eccrine poromas can present as multiple lesions, otherwise known as eccrine poromatosis.
Chiu, Melvin, Kim, Gene, Nguyen, Khoa
core  

Mantle cell lymphoma of the prostate

Canadian Urological Association Journal, 2013
Lymphoma of the prostate, either primary or secondary, is veryrare. We report the case of an 82-year-old man with symptoms ofbladder outlet obstruction presumably due to benign prostatehyperplasia (BPH). He underwent an uneventful transurethral resectionof the prostate.
Abuhjar, Abdussalam, Ronald G, Gerridzen
openaire   +3 more sources

Chronic lymphocytic leukemia with IGH::BCL3‐translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Approximately 1% of chronic lymphocytic leukemia (CLL) cases harbor a translocation juxtaposing the immunoglobulin heavy chain (IGH) and B‐cell lymphoma 3 (BCL3) loci. Aiming at comprehensive molecular characterization of IGH::BCL3‐positive B‐cell neoplasms, we here investigated samples from 84 patients using fluorescence in situ hybridization
Cosima Drewes, Cristina López, Juan Emilio Martinez‐Manjón, Nnamdi Okeke, Billy Jebaraj, Susanne Bens, Björn Brändl, Martin J. S. Dyer, Barbara Eichhorst, Anja Fischer, Kirsten Fischer, Sandra Robrecht, Michael Hallek, Selina Glaser, Sina Hillebrecht, Sandrine Jayne, Helene Kretzmer, Anja Mottok, Franz‐Josef Müller, Christof Schneider, Ole Ammerpohl, Coral del Val, Stephan Stilgenbauer, Eugen Tausch, Reiner Siebert   +24 more
wiley   +1 more source

Cutaneous lesions as presentation form of mantle cell lymphoma

Dermatology Reports, 2011
Mantle cell lymphoma is a type of no-Hodgkin lymphoma that affects extranodal areas, especially, bone narrow, digestive tract and Waldeyer ring. Here we report a case of mantle cell lymphoma IV Ann Arbor stage with cutaneous lesions on nasal dorsum and ...
Nayra Merino de Paz, Marina Rodriguez-Martin, Patricia Contreras Ferrer, Sonia Garcia-Hernandez, Nieves Hernandez de Leon, Antonio Martin-Herrera, Antonio Noda-Cabrera   +6 more
doaj   +1 more source

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia [PDF]

, 2015
Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins ...
A Puissant, AJ Mohamed, BD Smith, BJ Druker, C Chung, C Dos Santos, C Thiede, C Venkataraman, CC Smith, CK Hahn, F Heidel, F Honda, G Juliusson, H Kiyoi, HS Ma, J Adolfsson, JA Dubovsky, JA Dubovsky, JA Woyach, JA Woyach, JB Petro, K Fiedler, KU Birkenkamp, L Zaitseva, M Levis, M Nakao, ML Wang, N Feldhahn, NJ Horwood, PP Zarrinkar, Q Xu, RF Schlenk, RM Stone, S Knapper, S Meshinchi, SA Ezell, SA Rushworth, SA Rushworth, SA Rushworth, SA Rushworth, T Kindler, T Matsunaga, T Oellerich, T-l Gu, V Vijayan, W Gao, Y Alvarado, Y Baba, Y Yamamoto, Y-T Tai   +49 more
core   +2 more sources

The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival [PDF]

, 2008
Xiao Wang, Anna Asplund, Anna Porwit, Jenny Flygare, C. I. Edvard Smith, Birger Christensson, Birgitta Sander   +6 more
openalex   +1 more source

Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma

Hematology Reports, 2011
The determination of prognosis for B-Non- Hodgkin’s lymphoma (NHL) is known to be related to the multiple differences in tumor cell biology. Bcl-2 and Bcl-6 are two markers linked to germinal center B cells.
Hanan Mohamed Mahmoud, Yasmin Nabil Elsakhawy   +1 more
doaj   +1 more source

CRISPR Genome Editing and the Future of Leukaemia Immunotherapy

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims Leukaemia presents ongoing therapeutic challenges due to relapse and toxicity associated with standard treatments. By enabling more targeted and safer therapies, CRISPR genome editing is emerging as a powerful tool to address these issues.
Dejin Rai, Umberto Terranova
wiley   +1 more source

The Broad Spectrum HDAC Inhibitor PCI-24781 Induces Caspase- and ROS-Dependent Apoptosis and is Synergistic with Bortezomib in Lymphoma [PDF]

, 2008
We investigated the cytotoxicity and biology of the novel broad-spectrum hydroxamic acid-based histone deacetylase inhibitor (HDACi), PCI-24781. PCI-24781 was studied alone and combined with bortezomib in Hodgkin lymphoma (L428) and non-Hodgkin's ...
Andrew Evens, Joseph Buggy, Kevin David, Lauren Mauro, Leo Gordon, Mint Sirisawad, Richard Miller, Savita Bhalla, Sheila Prachand, Sriram Balasubramanian   +9 more
core   +1 more source